Category Archives: pricing

Show Me the Money: First New PPRS Payments in UK

By Leela Barham. The Pharmaceutical Price Regulation Scheme (PPRS) is a long-standing scheme where the pharmaceutical industry, represented by the Association of the British Pharmaceutical Industry (ABPI), negotiates with the Department of Health (DH) to agree how to indirectly manage the price of branded medicines. Its latest incarnation includes a brand new feature. Instead of […]
Also posted in Europe, Global, Guest Blog, Op-Ed | Tagged , , , , | Leave a comment

NICE in Conflict-of-Interest Controversy

They say the road to hell is paved with good intentions. The row in the UK over NICE’s call to doctors to increase the use of statins looked to be good example of this handy aphorism. That was until things took a potentially darker turn.
Also posted in Europe, healthcare | Tagged , , , | Leave a comment

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in Biotech, FDA, Guest Blog, healthcare, Legal, Market Access, Marketing, Regulatory, Strategy | Tagged , , | 1 Comment

Sanofi Responds to UK’s Value-Based Assessment Plans

By Leela Barham. The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.  VBA is what value-based pricing (VBP) has essentially morphed into. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 […]
Also posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

Turkey to See Renewed Multinational Investment, Says Report

Turkey is remains a key destination for foreign investment, and the next five years should see renewed interest from pharma multinationals, says a new report by CPhI Worldwide. Although the Turkish government’s price referencing system and fixed euro-lira conversion rate have presented a major obstacle for pharma growth, the report states that these pricing challenges […]
Also posted in Emerging Markets, Europe, Global, Manufacturing, R&D | Tagged , , | Leave a comment
  • Categories

  • Meta